Drug intelligence / Profile preview

PRG-2311

Development stage: Phase 1
Lead developer: Shenzhen Puruijin Biological Pharmaceutical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

PRG-2311 is an investigational **autologous dual-targeted CD19/BCMA chimeric antigen receptor T-cell therapy** developed by Shenzhen Pregene Biopharma. The product is manufactured from patient-derived mononuclear cells and administered following lymphodepleting conditioning. It is designed to deplete pathogenic CD19-positive B cells and BCMA-expressing plasmablasts and plasma cells, with the therapeutic goal of resetting autoreactive humoral immunity. PRG-2311 is being evaluated in an investigator-initiated early-phase clinical study for refractory lupus nephritis and refractory IgG4-related disease.

Other names: PRG 2311PRG2311PRG-2311

Targets

BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on PRG-2311.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRG-2311.

Explore the full profile